

Raymond L Woosley

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3635065/raymond-l-woosley-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198
papers

9,658
citations

50
h-index

92
g-index

215
ext. papers

10,404
ext. citations

7.4
avg, IF

5.84
L-index

#	Paper	IF	Citations
198	Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. <i>American Heart Journal</i> , 1986 , 111, 1088-93	4.9	432
197	Mechanism of the Cardiotoxic Actions of Terfenadine. <i>JAMA - Journal of the American Medical Association</i> , 1993 , 269, 1532	27.4	379
196	Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. <i>New England Journal of Medicine</i> , 1978 , 298, 1157-9	59.2	349
195	The FDA critical path initiative and its influence on new drug development. <i>Annual Review of Medicine</i> , 2008 , 59, 1-12	17.4	327
194	Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 231-8	6.1	319
193	Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. <i>Circulation</i> , 1996 , 94, 1471-4	16.7	262
192	Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 688-94	4.7	201
191	Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. <i>New England Journal of Medicine</i> , 1980 , 302, 877-82	59.2	174
190	QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. <i>Pharmacoepidemiology and Drug Safety</i> , 2005 , 14, 747-53	2.6	171
189	QTc interval prolongation associated with intravenous methadone. <i>Pain</i> , 2003 , 105, 499-506	8	166
188	Sotalol. <i>New England Journal of Medicine</i> , 1994 , 331, 31-8	59.2	164
187	Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. <i>Journal of Womens Health</i> , 1998 , 7, 547-57		160
186	Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. <i>Circulation</i> , 2000 , 101, 2200-5	16.7	159
185	Drug therapy. Flecainide. <i>New England Journal of Medicine</i> , 1986 , 315, 36-41	59.2	153
184	Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1639-1650	15.1	152
183	Cardiac actions of erythromycin: influence of female sex. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 280, 1774-6	27.4	151
182	Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. <i>American Journal of Cardiology</i> , 1980 , 46, 463-8	3	151

181	Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. <i>American Journal of Medicine</i> , 2003 , 114, 135-41	2.4	150
180	Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 67-75	15.1	148
179	Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. <i>American Journal of Cardiology</i> , 1981 , 48, 1133-40	3	146
178	Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 383-8	6.1	143
177	The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 662-9	6.1	138
176	The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. <i>New England Journal of Medicine</i> , 1990 , 322, 1764-8	59.2	133
175	Inappropriate prescribing for elderly Americans in a large outpatient population. <i>Archives of Internal Medicine</i> , 2004 , 164, 1621-5		127
174	Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. <i>Heart Rhythm</i> , 2006 , 3, 1003-7	6.7	123
173	Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 316, 1098-106	4.7	121
172	In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchietomized male rabbits. <i>Cardiovascular Research</i> , 2003 , 57, 28-36	9.9	115
171	The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 894-8	15.1	113
170	Greater quinidine-induced QTc interval prolongation in women. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 413-8	6.1	110
169	N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. <i>Carcinogenesis</i> , 1993 , 14, 675-8	4.6	109
168	Making medicines safer--the need for an independent drug safety board. <i>New England Journal of Medicine</i> , 1998 , 339, 1851-4	59.2	107
167	Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 477-81	1.7	99
166	Concentration-dependent pharmacologic properties of sotalol. <i>American Journal of Cardiology</i> , 1986 , 57, 1160-5	3	92
165	Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. <i>Clinical Pharmacology and Therapeutics</i> , 1976 , 19, 396-402	6.1	83
164	Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. <i>Journal of Cardiovascular Electrophysiology</i> , 1997 , 8, 1148-58	2.7	82

163	Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. <i>Archives of Internal Medicine</i> , 1999 , 159, 1733-40		78
162	Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. <i>Health Services Research</i> , 2006 , 41, 837-55	3.4	76
161	Amiodarone dosing: a proposal based on its pharmacokinetics. <i>American Heart Journal</i> , 1983 , 106, 951-64.9		76
160	Clinical features and basic mechanisms of quinidine-induced arrhythmias. <i>Journal of the American College of Cardiology</i> , 1986 , 8, 73A-78A	15.1	72
159	Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1977 , 22, 63-9	6.1	71
158	Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. <i>Drug Safety</i> , 2008 , 31, 525-36	5.1	70
157	Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. <i>Medical Care</i> , 2007 , 45, 456-62	3.1	70
156	Drug therapy. Tocainide. <i>New England Journal of Medicine</i> , 1986 , 315, 41-5	59.2	68
155	Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 282-7	6.1	63
154	Mechanism of cardiotoxicity of halofantrine. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 521-9	6.1	61
153	Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. <i>American Journal of Cardiology</i> , 1984 , 54, 9D-12D	3	61
152	The electrocardiographic effects of cetirizine in normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 295-301	6.1	55
151	Female gender is a risk factor for torsades de pointes in an in vitro animal model. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 34, 287-94	3.1	55
150	Acetylator phenotype and lupus erythematosus. <i>Clinical Pharmacokinetics</i> , 1981 , 6, 118-34	6.2	52
149	Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 636-42	6.1	51
148	Guanethidine. <i>New England Journal of Medicine</i> , 1976 , 295, 1053-7	59.2	50
147	Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1756-1764	15.1	50
146	Salivary analysis for determination of dextromethorphan metabolic phenotype. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 49, 410-9	6.1	49

145	Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1986 , 29, 843-50		49
144	Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. <i>Pharmacogenetics and Genomics</i> , 1993 , 3, 250-5		48
143	Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. <i>Europace</i> , 2013 , 15, 1042-9	3.9	47
142	Pharmacokinetics of sertraline across pregnancy and postpartum. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 646-53	1.7	46
141	Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. <i>Biochemical Pharmacology</i> , 2001 , 62, 41-9	6	46
140	Pharmacokinetics of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1978 , 41, 986-95	3	45
139	CredibleMeds.org: What does it offer?. <i>Trends in Cardiovascular Medicine</i> , 2018 , 28, 94-99	6.9	45
138	The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 86, 365-7	6.1	44
137	Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. <i>Journal of Cardiovascular Electrophysiology</i> , 1997 , 8, 1239-45	2.7	44
136	Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. <i>Journal of the American College of Cardiology</i> , 1983 , 2, 1134-40	15.1	44
135	Is dispersion of ventricular repolarization rate dependent?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 2405-11	1.6	43
134	Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 86, 425-9	6.1	42
133	Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. <i>American Journal of Cardiology</i> , 1986 , 57, 25B-33B	3	42
132	Terfenadine increases the QT interval in isolated guinea pig heart. <i>Journal of Cardiovascular Pharmacology</i> , 1995 , 25, 30-4	3.1	41
131	QT interval: a measure of drug action. <i>American Journal of Cardiology</i> , 1993 , 72, 36B-43B	3	41
130	Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. <i>Journal of Cardiovascular Pharmacology</i> , 1982 , 4, 765-9	3.1	38
129	Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. <i>American Heart Journal</i> , 1987 , 114, 1280-91	4.9	37
128	Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 206-15	3.8	36

127	Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia--a status report, 1987. <i>American Journal of Cardiology</i> , 1987 , 59, 54E-56E	3	35
126	Research at the interface of industry, academia and regulatory science. <i>Nature Biotechnology</i> , 2010 , 28, 432-3	44.5	34
125	Drug labeling revisions-guaranteed to fail?. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 284, 3047-9	27.4	33
124	Clinical implications of variable antiarrhythmic drug metabolism. <i>Pharmacogenetics and Genomics</i> , 1992 , 2, 2-11		32
123	Use of herbal remedies by diabetic Hispanic women in the southwestern United States. <i>Phytotherapy Research</i> , 2006 , 20, 250-5	6.7	31
122	Spectrum of antiarrhythmic response to encainide. <i>American Journal of Cardiology</i> , 1985 , 56, 887-91	3	31
121	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 519-25	3.8	30
120	Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. <i>Journal of the American College of Cardiology</i> , 1992 , 20, 259-64	15.1	30
119	Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1988 , 61, 1006-11	3	30
118	Clinical pharmacokinetics of disopyramide. <i>Clinical Pharmacokinetics</i> , 1986 , 11, 214-22	6.2	30
117	Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death. <i>Drug Safety</i> , 2017 , 40, 465-474	5.1	29
116	Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 210-20	6.1	29
115	QT prolongation and arrhythmia suppression. <i>American Heart Journal</i> , 1985 , 109, 411-5	4.9	29
114	Disposition kinetics of encainide and metabolites. <i>American Journal of Cardiology</i> , 1986 , 58, 4C-9C	3	29
113	Assessing cardiovascular drug safety for clinical decision-making. <i>Nature Reviews Cardiology</i> , 2013 , 10, 330-7	14.8	28
112	Centers for education and research in therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 249-55	6.1	28
111	Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 398-405	6.1	28
110	Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. <i>American Journal of Cardiology</i> , 1984 , 54, 654-8	3	28

109	Flecainide dose-response relations in stable ventricular arrhythmias. <i>American Journal of Cardiology</i> , 1984 , 53, 59B-65B	3	28
108	Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 224-7	2.9	27
107	Normal distribution of acetylation phenotypes in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1978 , 21, 192-5		27
106	An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. <i>Drug Safety</i> , 2016 , 39, 433-41	5.1	26
105	Potential determinants of prescribers' drug-drug interaction knowledge. <i>Research in Social and Administrative Pharmacy</i> , 2008 , 4, 355-66	2.9	26
104	Encainide disposition in patients with renal failure. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 40, 64-70	6.1	24
103	Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. <i>American Journal of Cardiology</i> , 1982 , 50, 305-12	3	24
102	Diagramming patients' views of root causes of adverse drug events in ambulatory care: an online tool for planning education and research. <i>Patient Education and Counseling</i> , 2006 , 62, 302-15	3.1	23
101	Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1987 , 59, 19E-25E	3	23
100	Potential drug-drug interactions within Veterans Affairs medical centers. <i>American Journal of Health-System Pharmacy</i> , 2007 , 64, 1500-5	2.2	22
99	Pharmacokinetics of moricizine HCl. <i>American Journal of Cardiology</i> , 1987 , 60, 35F-39F	3	22
98	Assessment and reporting of clinical pharmacology information in drug labeling. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 196-200	6.1	21
97	Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 91-9	6.1	21
96	Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1986 , 29, 508-14		21
95	Gender and age differences in medications dispensed from a national chain drugstore. <i>Journal of Women's Health</i> , 2008 , 17, 735-43	3	20
94	Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. <i>Pharmacogenetics and Genomics</i> , 1993 , 3, 322-7		20
93	Encainide disposition in patients with chronic cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 40, 148-54	6.1	20
92	Pharmacokinetics and nondialyzability of mexiletine in renal failure. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 37, 649-53	6.1	19

91	The implications of procainamide metabolism to its induction of lupus. <i>Arthritis and Rheumatism</i> , 1981 , 24, 994-1003		19
90	Community pharmacy managers' perception of computerized drug-drug interaction alerts. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006 , 46, 148-53	1.7	18
89	Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. <i>Clinical Therapeutics</i> , 2011 , 33, 36-45	3.5	17
88	Development of a comprehensive detection method for medicinal and toxic plant species. <i>American Journal of Botany</i> , 2006 , 93, 566-74	2.7	17
87	Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 49, 698-700	6.1	17
86	Relation between ventricular function and antiarrhythmic responses to sotalol. <i>American Journal of Cardiology</i> , 1989 , 64, 943-5	3	17
85	Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 553-61	6.1	17
84	Overview of the clinical pharmacology of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1988 , 61, 61A-69A	3	17
83	Amiodarone-induced lymphocyte toxicity and mitochondrial function. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 94-100	3.1	17
82	Medical decision support systems and therapeutics: The role of autopilots. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 161-4	6.1	17
81	Analysis of potential adverse drug reactions--a case of mistaken identity. <i>American Journal of Cardiology</i> , 1994 , 74, 208-9	3	16
80	New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 1130-40	15.1	16
79	Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. <i>Journal of Cardiovascular Pharmacology</i> , 1989 , 14, 364-73	3.1	16
78	Centers for education and research on therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 4-10	6.1	15
77	Importance of metabolites in antiarrhythmic therapy. <i>American Journal of Cardiology</i> , 1983 , 52, 3C-7C	3	15
76	Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide 1983 , 23, 179-91		15
75	Evidence for the biotransformation of procainamide to a reactive metabolite. <i>Toxicology and Applied Pharmacology</i> , 1979 , 50, 9-16	4.6	15
74	Workload and availability of technology in metropolitan community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006 , 46, 154-60	1.7	14

73	S-mephenytoin hydroxylation phenotypes in a Jordanian population. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 542-7	6.1	14
72	d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism. <i>Clinical Pharmacology and Therapeutics</i> , 1993 , 53, 436-42	6.1	14
71	Clinical pharmacokinetics of moricizine. <i>American Journal of Cardiology</i> , 1990 , 65, 21D-25D; discussion 68D-71D	3	14
70	Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. <i>American Heart Journal</i> , 1984 , 107, 585-9	4.9	14
69	Determination of clemastine in human plasma by gas chromatography with nitrogen-phosphorus detection. <i>Biomedical Applications</i> , 2000 , 744, 177-81		13
68	Teaching objectives for fellowship programs in clinical electrophysiology. <i>Journal of the American College of Cardiology</i> , 1988 , 12, 255-61	15.1	13
67	Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 313-21	6.1	13
66	CAST: implications for drug development. <i>Clinical Pharmacology and Therapeutics</i> , 1990 , 47, 553-6	6.1	12
65	Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. <i>Journal of Cardiovascular Pharmacology</i> , 1984 , 6, 588-95	3.1	12
64	Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk. <i>Journal of Electrocardiology</i> , 2015 , 48, 533-8	1.4	11
63	Clarification to the www.qtdrugs.org updated lists. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 423-4	2.6	11
62	Discovering adverse reactions: why does it take so long?. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 287-9	6.1	11
61	Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1988 , 62, 9H-17H	3	11
60	Tocainide plus quinidine for treatment of ventricular arrhythmias. <i>American Journal of Cardiology</i> , 1988 , 61, 570-3	3	11
59	Indications for antiarrhythmic therapy: a wealth of controversy, a dearth of data. <i>Annals of Internal Medicine</i> , 1988 , 108, 450-2	8	11
58	Clinical importance of metabolites of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1984 , 53, 248-51	3	11
57	Brief report: development of a prescription medication information webliography for consumers. <i>Journal of General Internal Medicine</i> , 2006 , 21, 1313-6	4	10
56	The clinical value of FDA class C drugs approved from 1981 to 1988. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 577-82	6.1	10

55	Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 30-6	1.6	10
54	Clinical pharmacokinetics of encainide. <i>Clinical Pharmacokinetics</i> , 1988 , 14, 141-7	6.2	10
53	Potential applications of free drug level monitoring in cardiovascular therapy. <i>Clinical Pharmacokinetics</i> , 1984 , 9 Suppl 1, 79-83	6.2	10
52	Agranulocytosis during combined procainamide and phenytoin therapy. <i>Southern Medical Journal</i> , 1979 , 72, 1599-601	0.6	10
51	Control of ventricular preexcitation and associated arrhythmias by encainide. <i>American Heart Journal</i> , 1981 , 102, 794-7	4.9	10
50	Electropharmacologic synergism with mexiletine and quinidine. <i>Journal of Cardiovascular Pharmacology</i> , 1986 , 8, 840-6	3.1	10
49	Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 1785-91	2.9	9
48	Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 411-7	6.1	8
47	Indications for different modes of surgical therapy in medically refractory ventricular arrhythmias. <i>Annals of Surgery</i> , 1986 , 203, 679-84	7.8	8
46	Bretylum: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. <i>American Journal of Cardiology</i> , 1985 , 55, 395-401	3	8
45	Effects of concentration and steric configuration of propranolol on AV conduction and ventricular repolarization in the dog. <i>Journal of Cardiovascular Pharmacology</i> , 1981 , 3, 692-703	3.1	8
44	Metabolism of L-methionine- 35 S in zinc-deficient rats. <i>Journal of Nutrition</i> , 1972 , 102, 1181-6	4.1	8
43	The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 499-508	6.1	7
42	The antiarrhythmic activity of meobentine sulfate in man. <i>Journal of Cardiovascular Pharmacology</i> , 1984 , 6, 650-6	3.1	7
41	Selection of an antiarrhythmic drug for a sudden-death-prevention trial. <i>American Heart Journal</i> , 1982 , 103, 737-45	4.9	7
40	Arrhythmogenic foods - A growing medical problem. <i>Trends in Cardiovascular Medicine</i> , 2020 , 30, 310-312	5.9	7
39	Identification of populations likely to benefit from pharmacogenomic testing. <i>Pharmacogenetics and Genomics</i> , 2020 , 30, 91-95	1.9	6
38	One hundred years of drug regulation: where do we go from here?. <i>Annual Review of Pharmacology and Toxicology</i> , 2013 , 53, 255-73	17.9	6

37	Regulatory and reimbursement innovation. <i>Science Translational Medicine</i> , 2013 , 5, 176cm3	17.5	6
36	LCMS Analysis of Sertraline and Its Active Metabolite in Human Serum Using a Silica Column with a Non-Aqueous Polar Mobile Phase. <i>Chromatographia</i> , 2011 , 73, 749-754	2.1	6
35	Survey of clinical pharmacology training in the United States and Canada. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 1-7	6.1	5
34	Immediate- versus controlled-release disopyramide: importance of saturable binding. <i>Clinical Pharmacology and Therapeutics</i> , 1993 , 54, 16-22	6.1	5
33	Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 46, 324-34	6.1	5
32	Recurrent ventricular tachycardia in the absence of overt heart disease: clinical characteristics and response to drug therapy. <i>Southern Medical Journal</i> , 1981 , 74, 1090-4	0.6	5
31	Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment. <i>Therapeutic Innovation and Regulatory Science</i> , 2014 , 48, 236-245	1.2	4
30	Correction to Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States. <i>Health Services Research</i> , 2006 , 41, 856-859	3.4	4
29	From bench to bedside: role of gender-based therapeutics in the clinical care of women. <i>Journal of Women's Health</i> , 1998 , 7, 21-3		4
28	Longitudinal prescribing patterns of psychotropic drugs in nursing home residents.. <i>Experimental and Clinical Psychopharmacology</i> , 1996 , 4, 224-233	3.2	4
27	Adenosine A1-receptor occupancy predicts A1-receptor antagonist effects of N-0861. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 536-41	6.1	3
26	Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing home residents. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 688-94	3.2	3
25	Biological sex analysis in clinical research. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2000 , 9, 933-4		3
24	Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol. <i>Drug Safety</i> , 2019 , 42, 907-913	5.1	2
23	Community pharmacy and pharmacist staff call center: assessment of medication safety and effectiveness. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011 , 51, 82-9	1.7	2
22	Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs. <i>Cardiac Electrophysiology Clinics</i> , 2010 , 2, 341-358	1.4	2
21	Time to replace Bazett's QT-correction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009 , 32, 1379-80	1.6	2
20	The role of Internet-based registries in tandem with genetic screening for the study of drug-induced arrhythmias. <i>Current Therapeutic Research</i> , 2001 , 62, 787-795	2.4	2

19	Antiarrhythmic therapy: clinical pharmacology update. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 295-305	2
18	Mexiletine for resistant ventricular tachycardia: Comparison with lidocaine and enhancement of efficacy by combination with quinidine. <i>American Journal of Cardiology</i> , 1981 , 47, 438	3 2
17	Antiarrhythmic effects of the quaternary propranolol analog that does not induce beta-adrenergic blockade. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 33-40	6.1 2
16	The Integration of Pharmacodynamics and Pharmacokinetics in Rational Drug Development 1993 , 225-238	2
15	Use of Drugs in Long QT Syndrome Type 3 and Brugada Syndrome. <i>Cardiac Electrophysiology Clinics</i> , 2014 , 6, 811-817	1.4 1
14	They are from the government and they really are here to help you. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 142-3	2.9 1
13	Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 49, 314-21	6.1 1
12	Drug-Induced Long QT Syndrome and Torsades de Pointes 2020 , 185-200	1
11	Assisted prescribing: Clinical decision support with MedSafety Scan now available. <i>Trends in Cardiovascular Medicine</i> , 2020 , 32, 44-44	6.9 0
10	Markers of ventricular repolarization and overall mortality in sleep disordered breathing.. <i>Sleep Medicine</i> , 2022 , 95, 9-15	4.6 0
9	It is important research, but why is it necessary?. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 297-96.1	
8	I.V. Amiodarone: What Do We Really Know About It?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998 , 2, 61-63	
7	The translational path includes the FDA's critical path. <i>Journal of Cardiovascular Translational Research</i> , 2008 , 1, 188-9	3.3
6	Regulating manufacturer-affiliated communication in the information age. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 65, 593-7	6.1
5	Message from the Government Affairs Committee. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 486-488	6.1
4	Efficacy and safety of ACC-9358, a new antiarrhythmic agent. <i>American Journal of Cardiology</i> , 1990 , 65, 932-4	3
3	An Information Technology Architecture for Drug Effectiveness Reporting and Post-Marketing Surveillance	131-145
2	Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval. <i>Cureus</i> , 2020 , 12, e9668	1.2

- 1 Drug-induced torsades de pointes **2022**, 39-50